Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Potential threat of drug-resistant and vaccine-escape HBV mutants to public health.

Teo CG, Locarnini SA.

Antivir Ther. 2010;15(3 Pt B):445-9. doi: 10.3851/IMP1556.

PMID:
20516564
2.

Molecular genesis of drug-resistant and vaccine-escape HBV mutants.

Locarnini SA, Yuen L.

Antivir Ther. 2010;15(3 Pt B):451-61. doi: 10.3851/IMP1499. Review.

PMID:
20516565
3.

Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.

Lacombe K, Boyd A, Gozlan J, Lavocat F, Girard PM, Zoulim F.

Antivir Ther. 2010;15(3 Pt B):493-7. doi: 10.3851/IMP1495. Review.

PMID:
20516570
5.

Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy.

Yeh CT.

Antivir Ther. 2010;15(3 Pt B):471-5. doi: 10.3851/IMP1552. Review.

PMID:
20516567
6.
7.

Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity.

Sheldon J, Ramos B, Garcia-Samaniego J, Rios P, Bartholomeusz A, Romero M, Locarnini S, Zoulim F, Soriano V.

J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):279-82.

PMID:
18167643
8.

Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.

Sayan M, Akhan SC.

Int J Infect Dis. 2011 Oct;15(10):e722-6. doi: 10.1016/j.ijid.2011.05.019. Epub 2011 Jul 23.

9.

Hepatitis B virus escape mutants induced by antiviral therapy.

Sheldon J, Soriano V.

J Antimicrob Chemother. 2008 Apr;61(4):766-8. doi: 10.1093/jac/dkn014. Epub 2008 Jan 24. Review.

10.
11.

Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients.

Ramos B, Núñez M, Martín-Carbonero L, Sheldon J, Rios P, Labarga P, Romero M, Barreiro P, García-Samaniego J, Soriano V.

J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):557-61.

PMID:
17224847
12.

[Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].

Sayan M, Hülagü S, Akhan SC, Sentürk O, Meriç M, Cekmen M.

Mikrobiyol Bul. 2009 Jul;43(3):425-32. Turkish.

PMID:
19795617
13.

Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.

Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N.

J Infect Dis. 2008 Oct 15;198(8):1150-8. doi: 10.1086/591941.

14.

Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.

Wakil SM, Kazim SN, Khan LA, Raisuddin S, Parvez MK, Guptan RC, Thakur V, Hasnain SE, Sarin SK.

J Med Virol. 2002 Nov;68(3):311-8.

PMID:
12226816
15.

Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.

Quiros-Roldan E, Calabresi A, Lapadula G, Tirelli V, Costarelli S, Cologni G, Zaltron S, Puoti M, Carosi G, Torti C.

Antivir Ther. 2008;13(3):341-8.

PMID:
18572746
16.

Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.

Amini-Bavil-Olyaee S, Sheldon J, Lutz T, Trautwein C, Tacke F.

AIDS. 2009 Jan 14;23(2):268-72. doi: 10.1097/QAD.0b013e3283224316.

PMID:
19098499
17.

The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.

Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM.

Antivir Ther. 2006;11(4):447-55.

PMID:
16856618
18.

Hepatitis B virus genetic diversity.

Echevarría JM, Avellón A.

J Med Virol. 2006;78 Suppl 1:S36-42.

PMID:
16622876
19.

Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?

Clements CJ, Coghlan B, Creati M, Locarnini S, Tedder RS, Torresi J.

Bull World Health Organ. 2010 Jan;88(1):66-73. doi: 10.2471/BLT.08.065722. Epub 2009 Oct 23.

20.

Coevolution and HBV drug resistance.

Khudyakov Y.

Antivir Ther. 2010;15(3 Pt B):505-15. doi: 10.3851/IMP1515. Review.

PMID:
20516572
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk